1. Product Overview & Specifications

Glatiramer Acetate (CAS 147245-92-9), a synthetic polypeptide mixture, is FDA-approved for relapsing-remitting multiple sclerosis (RRMS) treatment.

2. Key Applications & Clinical Uses

Therapeutic Applications:

• First-line treatment for RRMS (50% reduction in annual relapse rate)
• MRI-monitored disease activity suppression
• Immune tolerance induction in autoimmune research

Mechanism of Action:

Competes with myelin antigens to:

1. Modulate antigen-presenting cells
2. Induce regulatory T-cells (T_reg)
3. Shift cytokine profile from pro-inflammatory to anti-inflammatory

3. Usage Guidelines & Best Practices

Clinical Administration:

Research Protocols:

• Experimental autoimmune encephalomyelitis (EAE) models: 250μg/mouse in PBS
• In vitro T-cell assays: 10-100μg/mL concentrations

4. Real-World Case Studies

Case 1: Hospital MS Clinic

Challenge: 34-year-old female with 2 relapses/year despite interferon therapy
Solution: Switched to Glatiramer Acetate 40mg 3x/week
Outcome: 18-month relapse-free period with stable MRI findings

5. Customer Success Stories

Biopharma Innovator (USA)

Developed novel GA-derived nanoparticles achieving:
– 3x longer plasma half-life
– 40% reduction in injection-site reactions

University Research Team (Germany)

Published Nature Immunology paper demonstrating:
– GA’s effect on dendritic cell metabolism
– Metabolic reprogramming of Th17 cells

6. Request Customized Solutions

Contact our MS therapy experts:
Email: info@vivalr.com
Phone: (86) 15866781826

Request:
– Bulk pricing for clinical trials
– Custom formulation services
– Stability testing data packages